Brain Glucose Hypometabolism and Oxidative Stress in Preclinical Alzheimer's Disease
Lisa Mosconi
Department of Psychiatry, New York University School of Medicine, New York, USA
Search for more papers by this authorMony J. De Leon
Department of Psychiatry, New York University School of Medicine, New York, USA
Nathan Kline Institute, Orangeburg, New York, USA
Search for more papers by this authorLisa Mosconi
Department of Psychiatry, New York University School of Medicine, New York, USA
Search for more papers by this authorMony J. De Leon
Department of Psychiatry, New York University School of Medicine, New York, USA
Nathan Kline Institute, Orangeburg, New York, USA
Search for more papers by this authorAbstract
One of the main features of Alzheimer's disease (AD) is the severe reduction of the cerebral metabolic rate for glucose (CMRglc). In vivo imaging using positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDG–PET) demonstrates consistent and progressive CMRglc reductions in AD patients, the extent and topography of which correlate with symptom severity. Increasing evidence suggests that CMRglc reductions occur at the preclinical stages of AD. CMRglc reductions were observed on FDG–PET before the onset of disease in several groups of at-risk individuals, including patients with mild cognitive impairment (MCI), often a prodrome to AD; presymptomatic individuals carrying mutations responsible for early-onset familial AD; cognitively normal elderly individuals followed for several years until they declined to MCI and eventually to AD; normal, middle-aged individuals who expressed subjective memory complaints and were carriers of the apolipoprotein E epsilon-4 allele, a strong genetic risk factor for late-onset AD. However, the causes of the early metabolic dysfunction forerunning the onset of AD are not known. An increasing body of evidence indicates a deficient or altered energy metabolism that could change the overall oxidative microenvironment for neurons during the pathogenesis and progression of AD, leading to alterations in mitochondrial enzymes and in glucose metabolism in AD brain tissue. The present paper reviews findings that implicate hypometabolism and oxidative stress as crucial players in the initiation and progression of synaptic pathology in AD.
References
- 1 Mirra, S.S., A. Heyman, D. Mckeel, et al . 1991. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurol. 41: 479–486.
- 2 Price, J.L. & J.C. Morris. 1999. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann. Neurol. 45: 358–368.
- 3 Braak, H. & E. Braak. 1996. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathologica 92: 197–201.
- 4 Delacourte, A., J.P. David, N. Sergeant, et al . 1999. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurol. 52: 1158–1165.
- 5 Morris, J.C., M. Storandt, D.W. Mckeel, et al . 1996. Cerebral amyloid deposition and diffuse plaques in “normal” aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurol. 46: 707–719.
- 6 Braak, H. & E. Braak. 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 82: 239–259.
- 7 Crystal, H.A., D. Dickson, P. Davies, et al . 2000. The relative frequency of “dementia of unknown etiology” increases with age and is nearly 50% in nonogenerians. Arch. Neurol. 57: 713–719.
- 8 Crystal, H., D. Dickson, P. Fuld, et al . 1988. Clinico-pathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer's disease. Neurol. 38: 1682–1687.
- 9 Price, J.L., A.I. Ko, M.J. Wade, et al . 2001. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol. 58: 1395–1402.
- 10 Morrison, J.H. & P.R. Hof. 1997. Life and death of neurons in the aging brain. Science 278: 412–419.
- 11 Hyman, B.T., G.W. Van Hoesen, A.R. Damasio & C.L. Barnes. 1984. Alzheimer's disease: Cell-specific pathology isolates the hippocampal formation. Science 225: 1168–1170.
- 12 Arriagada, P.V., K. Marzloff & B.T. Hyman. 1992. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurol. 42: 1681–1688.
- 13 Giannakopoulos, P., P.R. Hof, S. Mottier, et al . 1994. Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: Retrospective clinicopathological evaluation of a 10-year autopsy population. Acta Neuropathologica 87: 456–468.
- 14 Terry, R.D., E. Masliah, D.P. Salmon, et al . 1991. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30: 572–580.
- 15 Mattson, M.P. & T. Magnus. 2006. Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 7: 278–294.
- 16 Hanefeld, M., N. Marx, A. Pfutzner, et al . 2007. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: The PIOSTAT Study. J. Am. College Cardiol. 49: 290–297.
- 17 De Leon, M.J., A. Convit, O.T. Wolf, et al . 2001. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. USA 98: 10966–10971.
- 18 Mosconi, L., S. De Santi, J. Li, et al . 2008. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging 29(5): 676–692. doi:DOI: 10.1016/j.neurobiolaging.2006.12.008.
- 19 Small, G.W., J.C. Mazziotta, M.T. Collins, et al . 1995. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273: 942–947.
- 20 Reiman, E.M., R.J. Caselli, L.S. Yun, et al . 1996. Preclinical evidence of Alzheimer's disease in persons homozygous for the E4 allele for apolipoprotein E. N. Engl. J. Med. 334: 752–758.
- 21 Mosconi, L., S. Sorbi, M.J. De Leon, et al . 2006. Hypometabolism exceeds atrophy in presymptomatic early-onset Familial Alzheimer's disease. J. Nucl. Med. 47: 1778–1786.
- 22 Blass, J.P. 2002. Alzheimer's disease and Alzheimer's dementia: Distinct but overlapping entities. Neurobiol. Aging 23: 1077–1084.
- 23 Grady, C.L., J.V. Haxby, N.L. Schlageter, et al . 1986. Stability of metabolic and neuropsychological asymmetries in dementia of the Alzheimer type. Neurol. 36: 1390–1392.
- 24 Haxby, J.V., C.L. Grady, E. Koss, et al . 1990. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch. Neurol. 47: 753–760.
- 25 Desgranges, B., J.-C. Baron, V. De La Sayette, et al . 1998. The neural substrates of memory systems impairment in Alzheimer's Disease a PET study of resting brain glucose utilization. Brain 121: 611–631.
- 26 Sheu, R.K., R. Mohs, V. Haraoutunian & J.P. Blass. 2001. Correlation of the clinical severity of Alzheimer's disease with an aberration in mitochondrial DNA (mtDNA). J. Mol. Neurosci. 16: 41–48.
- 27 Lambert, M.P., A.K. Barlow, B.A. Chromy, et al . 1998. Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95: 6448–6453.
- 28 Blass, J.P. 2000. The mitochondrial spiral. An adequate cause of dementia in the Alzheimer's syndrome. Ann. New York Acad. Sci. 924: 170–183.
- 29 Behl, C. & C. Behl. 1999. Alzheimer's disease and oxidative stress: Implications for novel therapeutic approaches. Progress Neurobiol. 57: 301–323.
- 30 Rapoport, S.I. 1999. In vivo PET imaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer's disease [abstract]. Eur. Arch. Psych. Clin. Neurosci. 249: 46–55.
- 31 Gibson, G.E. 2002. Interactions of oxidative stress with cellular calcium dynamics and glucose metabolism in Alzheimer's disease. Free Radical Biol. Med. 32: 1061–1070.
- 32 Keller, J.N., Z. Pang, J.W. Geddes, et al . 1997. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: Role of the lipid peroxidation product 4-hydroxynonenal. J. Neurochem. 69: 273–284.
- 33 Keller, J.N., R.J. Mark, A.J. Bruce, et al . 1997. 4-hydroxynonenal, an aldehyde product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes. Neurosci. 80: 685–696.
- 34 Sokoloff, L. 1977. Relation between physiological functions and energy metabolism in the central nervous system. J. Neurochem. 29: 13–26.
- 35 Attwell, D. & C. Iadecola. 2002. The neural basis of functional brain imaging signals. Trends Neurosci. 25: 621–625.
- 36 Malonek, D. & A. Grinvald. 1999. Interactions between electrical activity and cortical microcirculation revealed by imaging spectrosopy: Implications for functional brain mapping. Science 272: 551–554.
- 37 Rocher, A.B., F. Chapon, X. Blaizot, et al . 2004. Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: A study in baboons. Neuroimage 20: 1894–1898.
- 38 Mosconi, L. 2005. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. Eur. J. Nucl. Med. 32: 486–510.
- 39 Friedland, R.P., T.F. Budinger, E. Ganz, et al . 1983. Regional cerebral metabolic alterations in dementia of the Alzheimer type: Positron emission tomography with [18F] fluorodeoxyglucose. J. Comp. Assist. Tomogr. 7: 590–598.
- 40 Minoshima, S., B. Giordani, S. Berent, et al . 1997. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 42: 85–94.
- 41 Foster, N.L., T.N. Chase, L. Mansi, et al . 1984. Cortical abnormalities in Alzheimer's disease. Ann. Neurol. 16: 649–654.
- 42 Ferris, S.H., M.J. De Leon, A.P. Wolf, et al . 1980. Positron emission tomography in the study of aging and senile dementia. Neurobiol. Aging 1: 127–131.
- 43 Mazziotta, J.C. & M.E. Phelps. 1986. Positron emission tomography studies of the brain. In Positron Emission Tomography & Autoradiography: Principles & Applications for the Brain & Heart. M.E. Phelps, J.C. Mazziotta & H. Schelbert, Eds.: 493–579. Raven Press. New York , NY .
- 44 Silverman, D.H.S., G.W. Small, C.Y. Chang, et al . 2001. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 286: 2120–2127.
- 45 De Leon, M.J., T. Mcrae, H. Rusinek, et al . 1997. Cortisol reduces hippocampal glucose metabolism in normal elderly but not in Alzheimer's disease. J. Clin. Endocrinol. Metab. 82: 3251–3259.
- 46 Ouchi, Y., S. Nobezawa, H. Okada, et al . 1998. Altered glucose metabolism in the hippocampal head in memory impairment. Neurol. 51: 136–142.
- 47 De Santi, S., M.J. De Leon, H. Rusinek, et al . 2001. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol. Aging 22: 529–539.
- 48 Nestor, P.J., T.D. Fryer, P. Smielewski & J.R. Hodges. 2003. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann. Neurol. 54: 343–351.
- 49 Mosconi, L., W.H. Tsui, S. De Santi, et al . 2005. Reduced hippocampal metabolism in mild cognitive impairment and Alzheimer's disease: Automated FDG-PET image analysis. Neurol. 64: 1860–1867.
- 50 Mosconi, L., S. De Santi, Y. Li, et al . 2006. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. Eur. J. Nucl. Med. Mol. Imaging 33: 210–221.
- 51 Mosconi, L., W.H. Tsui, H. Rusinek, et al . 2007. Quantitation, regional vulnerability and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 34: 1467–1479.
- 52 Petersen, R.C., G.E. Smith, S.C. Waring, et al . 1999. Mild cognitive impairment: Clinical characterization and outcome. Arch. Neurol. 56: 303–308.
- 53 Farrer, L.A., L.A. Cuples, J.L. Haines, et al . 1997. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. JAMA 278: 1349–1356.
- 54 Mosconi, L., S. De Santi, M. Brys, et al . 2007. Hypometabolism and altered CSF markers in normal ApoE E4 carriers with subjective memory complaints. Biol. Psychiatry 63(6): 609–618. doi:DOI: 10.1016/j.biopsych.2007.05.030.
- 55 Tanzi, R.E. & L. Bertram. 2001. New frontiers in Alzheimer's disease genetics. Neuron 32: 181–184.
- 56 Kennedy, A.M., S.K. Newman, R.S. Frackowiak, et al . 1995. Chromosome 14 linked familial Alzheimer's disease. A clinico-pathological study of a single pedigree. Brain 118: 185–205.
- 57 Kennedy, A.M., R.S.J. Frackowiak, S.K. Newman, et al . 1995. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci. Lett. 186: 17–20.
- 58 Petersen, R.C., J.C. Stevens, M. Ganguli, et al . 2001. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurol. 56: 1133–1142.
- 59 Gauthier, S., B. Reisberg, M. Zaudig, et al . 2006. Mild cognitive impairment. Lancet 367: 1262–1270.
- 60 Nestor, P.J., P. Scheltens & J.R. Hodges. 2004. Advances in the early detection of Alzheimer's disease. Nat. Med. 10: S34-S41.
- 61 Herholz, K., A. Nordberg, E. Salmon, et al . 1999. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 10: 494–504.
- 62 Arnaiz, E., V. Jelic, O. Almkvist, et al . 2001. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. NeuroReport 12: 851–855.
- 63 Chetelat, G., B. Desgranges, V. De La Sayette, et al . 2003. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurol. 60: 1374–1377.
- 64 Drzezga, A., N. Lautenschlager, H. Siebner, et al . 2003. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: A PET follow-up study. Eur. J. Nucl. Med. Molec. Imaging 30: 1104–1113.
- 65 Drzezga, A., T. Grimmer, M. Riemenschneider, et al . 2005. Prediction of individual outcome in MCI by means of genetic assessment and 18F-FDG PET. J. Nucl. Med. 46: 1625–1632.
- 66 Anchisi, D., B. Borroni, M. Franceschi, et al . 2005. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch. Neurology 62: 1728–1733.
- 67 Reed, B.R., W.J. Jagust, J.P. Seab & B.A. Ober. 1989. Memory and regional cerebral blood flow in mildly symptomatic Alzheimer's disease. Neurol. 39: 1537–1539.
- 68 Berent, S., B. Giordani, N. Foster, et al . 1999. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. J. Psychiat. Res. 33: 7–16.
- 69 Mosconi, L., D. Perani, S. Sorbi, et al . 2004. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurol. 63: 2332–2340.
- 70 Silverman, D.H.S., C.T. Truong, S.K. Kim, et al . 2003. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: Comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Mol. Genet. Metab. 80: 350–355.
- 71 Evans, D.A., H.H. Funkenstein, M.S. Albert, et al . 1989. Prevalence of Alzheimer's disease in a community population of older persons: Higher than previously reported. JAMA 262: 2551–2556.
- 72 Herholz, K., E. Salmon, D. Perani, et al . 2002. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17: 302–316.
- 73 Jagust, W., A. Gitcho, F. Sun, et al . 2006. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann. Neurol. 59: 673–681.
- 74 Corder, E.H., A.M. Saunders, W.J. Strittmatter, et al . 1993. Gene dose of apolipoprotein E type 4 Allele and the risk of Alzheimer's disease in late onset families. Science 261: 921–923.
- 75 Laws, S.M., E. Hone, S. Gandy & R.N. Martins. 2003. Expanding the association between the APOE gene and the risk of Alzheimer's disease: Possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J. Neurochem. 84: 1215–1236.
- 76 Small, G.W., L.M. Ercoli, D.H.S. Silverman, et al . 2000. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 97: 6037–6042.
- 77 Reiman, E.M., R.J. Caselli, K. Chen, et al . 2001. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98: 3334–3339.
- 78 Reiman, E.M., K. Chen, G.E. Alexander, et al . 2004. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. USA 101: 284–289.
- 79 Reiman, E.M., A. Uecker, R.J. Caselli, et al . 1998. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann. Neurol. 44: 288–291.
- 80 Gomez-Isla, T., R. Hollister, H. West, et al . 1997. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41: 17–24.
- 81 Pedersen, W.A., S.L. Chan & M.P. Mattson. 2000. A mechanism for the neuroprotective effect of apolipoprotein E: Isoform-specific modification by the lipid peroxidation product 4-hydroxynonenal. J. Neurochem. 74: 1426–1433.
- 82 Miyata, M. & J.D. Smith. 1996. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat. Genet. 14: 55–61.
- 83 Evans, K.C., E.P. Berger, C.G. Cho, et al . 1995. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer disease. Proc. Natl. Acad. Sci. USA 92: 763–767.
- 84 Geerlings, M.I., C. Jonker, L.M. Bouter, et al . 1999. Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. Am. J. Psychiat. 156: 531–537.
- 85 Buerger, K., R. Zinkowski, S.J. Teipel, et al . 2002. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Neurol. 59: 1267–1272.
- 86 Pratico, D., C.M. Clark, V.M. Lee, et al . 2000. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 48: 809–812.
- 87 Hansson, O., H. Zetterberg, P. Buchhave, et al . 2006. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol. 5: 228–234.
- 88 Decarli, C., J.R. Atack, M.J. Ball, et al . 1992. Post-mortem regional neurofibrillary tangle densities but not senile plaque densities are related to regional cerebral metabolic rates for glucose life in Alzheimer's disease patients. Neurodegeneration 1: 113–121.
- 89 Bradley, K.M., V.T. O'Sullivan, N.D. Soper, et al . 2002. Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain 125: 1772–1781.
- 90 Friedland, R.P., W.J. Jagust, R.H. Huesman, et al . 1989. Regional cerebral glucose transport and utilization in Alzheimer's disease. Neurol. 39: 1427–1434.
- 91 Jagust, W.J., J.P. Seab, R.H. Huesman, et al . 1991. Diminished glucose transport in Alzheimer's disease: Dynamic PET studies. J. Cereb. Blood Flow Metab. 11: 323–330.
- 92 Piert, M., R.A. Koeppe, B. Giordani, et al . 1996. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. J. Nucl. Med. 37: 201–208.
- 93 Phelps, M.E., S.C. Huang, E.J. Hoffman, et al . 1979. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-flouro-2-deoxy-D-glucose: Validation of method. Ann. Neurol. 6: 371–388.
- 94 Sokoloff, L., M. Reivich, C. Kennedy, et al . 1977. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 28: 897–916.
- 95 Rapoport, S.I. & C.L. Grady. 1993. Parametric in vivo brain imaging during activation to examine pathological mechanisms of functional failure in Alzheimer's disease. Int. J. Neurosci. 70: 36–59.
10.3109/00207459309000559 Google Scholar
- 96 Pietrini, P., M.L. Furey, G.E. Alexander, et al . 1999. Association between brain functional failure and dementia severity in Alzheimer's disease: Resting versus stimulation PET study. Am. J. Psychiat. 156: 470–473.
- 97 Patel, J.R. & G.J. Brewer. 2003. Age-related changes in neuronal glucose uptake in response to glutamate and beta-amyloid. J. Neurosci. Res. 72: 527–536.
- 98 Harman, D., D.E. Eddy & J. Noffsinger. 1976. Free radical theory of aging: Inhibition of amyloidosis in mice by antioxidants; possible mechanisms. J. Am. Geriatr. Soc. 24: 203–210.
- 99 Yang, Y., E.J. Mufson & K. Herrup. 2003. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J. Neurosci. 23: 2557–2563.
- 100 Ames, B.N., M.K. Shigenaga & T.M. Hagen. 1993. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. USA 90: 7915–7922.
- 101 Beal, M.F. 1995. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38: 357–366.
- 102 Jarvenpaa, T., I. Raiha, J. Kaprio, et al . 2003. A 90-year-old monozygotic female twin pair discordant for Alzheimer's disease. Neurobiol. Aging 24: 941–945.
- 103 Virta, J.J., M. Karrasch, J. Kaprio, et al . 2008. Cerebral glucose metabolism in dizygotic twin pairs discordant for Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 25: 9–16.